[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Suzhou UgeneX Therapeutics Co., Ltd.\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":45},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":27,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":5},"100616918","early-phase-1-ugx202-injection-in-patients-with-advanced-retinitis-pigmentosa-100616918",false,"NCT07311863","UGX202 Injection in Patients With Advanced Retinitis Pigmentosa","Study to Evaluate the Safety and Preliminary Efficacy of UGX202 Injection in Patients With Advanced Retinitis Pigmentosa","Inclusion Criteria:\n\n* Provide written informed consent form (ICF).\n* Age ≥18 years at ICF signing.\n* Diagnosed as non-syndromic RP；\n* BCVA \\> logMAR 1.9 (assessed by FrACT) in the study eye.\n* Confirmation of preserved memory of visual experience\n* Spherical equivalent between -9D and +6D.\n\nExclusion Criteria:\n\n* Prior gene therapy in either eye.\n* Received any interventional investigational drug within 90 days prior to screening.\n* Any Study eye disease or systemic disease judged by the investigator to affect visual function assessment.\n* Hypersensitivity to corticosteroids, intolerance to corticosteroid regimen, active concurrent infection contraindicating treatment.\n* History or tendency of psychiatric disorders impacting safety and\u002For efficacy assessment.\n* Any other factor deemed unsuitable by the investigator.","ALL","18 Years",{"count":19,"type":20},6,"ESTIMATED","INTERVENTIONAL",[23],"EARLY_PHASE1","The primary objective of this clinical trial is to evaluate the safety and tolerability of a single intravitreal injection of the gene therapy drug UGX202 in patients with advanced RP. The secondary objective is, to assess the preliminary efficacy of a single intravitreal injection of the gene therapy drug UGX202 in treating patients with advanced RP.",[26],"Retinitis Pigmentosa (RP)",[28,29,30,31,32],"UGX202","UGENEXIIT002","retinitis pigmentosa","RP","AAV","NOT_YET_RECRUITING","2025-12-16",{"date":36,"type":37},"2025-12-31","ACTUAL",{"date":39,"type":20},"2026-01",{"date":41,"type":20},"2027-03",{"name":43,"class":44},"Suzhou UgeneX Therapeutics Co., Ltd.","OTHER",""]